Cytotoxic cancer therapy is known to be associated with CHIP (Coombs et al., 2017; Gillis et al., 2017; Slavin et al., 2019; Takahashi et al., 2017) and should be considered by ordering providers as a potential contributor to acquisition of somatic TP53 PVs. Here, TP53 is linked to cancer.